Ultrasensitive MicroRNA Detection Combining Reduced Graphene Oxide Electrolyte‐Gated Transistors and Machine Learning

Why It Matters

The technology delivers laboratory‑grade sensitivity in a handheld format, enabling earlier, more accessible disease screening and reducing reliance on complex PCR equipment.

Key Takeaways

• rGO electrolyte-gated transistors enable label‑free miRNA sensing
• Machine learning extracts features from transistor transfer curves
• Detection limit reaches 0.098 amol L⁻¹ for miR‑34 family
• Perfect discrimination between fully matched and mismatched sequences
• Platform supports 0.1–1000 amol L⁻¹ dynamic range

Pulse Analysis

MicroRNAs have emerged as powerful biomarkers because their expression patterns reflect the onset and progression of cancers and neurological disorders. Traditional detection relies on reverse‑transcription polymerase chain reaction, which demands expensive reagents, temperature cycling, and skilled operators, limiting its use outside centralized labs. The demand for rapid, low‑cost, and highly sensitive assays has driven research into nanomaterial‑based sensors that can translate molecular binding events into measurable electrical signals.

Reduced graphene oxide electrolyte‑gated transistors offer a unique combination of high carrier mobility and a large surface‑to‑volume ratio, making them ideal for label‑free detection of nucleic acids. By functionalizing the rGO channel with complementary DNA probes, target miRNAs induce a detectable shift in the transistor’s transfer curve. The real innovation lies in coupling this hardware with machine‑learning algorithms that deconvolute subtle variations across multiple curve parameters, extracting physically meaningful features that differentiate perfectly matched sequences from single‑base mismatches. This multidimensional analysis dramatically improves selectivity without additional chemical steps.

The integration of rGO‑EGTs and AI creates a portable platform capable of sub‑femtomolar detection, a threshold previously attainable only in specialized laboratories. For clinicians, this means earlier diagnosis of malignancies and neurodegenerative diseases at the point of care, potentially improving treatment outcomes and reducing healthcare costs. From a market perspective, the technology aligns with the growing demand for decentralized diagnostics, positioning it for rapid adoption in telemedicine, wearable health monitors, and field‑deployed testing kits. Continued refinement of the sensor architecture and expansion to broader miRNA panels could further solidify its role in next‑generation precision medicine.